about
Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementPathways for outpatient management of venous thromboembolism in a UK centreDiagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry.The use of Macitentan in Fontan circulation: a case report.Dynamic contrast-enhanced magnetic resonance imaging in patients with pulmonary arterial hypertension.Definitions and diagnosis of pulmonary hypertension.Connective tissue disease-associated pulmonary arterial hypertension.Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension.CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry.Right ventricular sex differences in patients with idiopathic pulmonary arterial hypertension characterised by magnetic resonance imaging: pair-matched case controlled study.Longitudinal and transverse right ventricular function in pulmonary hypertension: cardiovascular magnetic resonance imaging study from the ASPIRE registry.Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis.Pregnancy and pulmonary hypertension: a practical approach to management.Management dilemmas in acute pulmonary embolism.Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach.Lung morphology assessment with balanced steady-state free precession MR imaging compared with CT.Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension.Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic-pathophysiologic classification.Combining creative writing and narrative analysis to deliver new insights into the impact of pulmonary hypertension.Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension.Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.Management of acute pulmonary embolism.Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertensionPulmonary hypertension in COPD: results from the ASPIRE registry.Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre.Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry.Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension.The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension.British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations.An official European Respiratory Society statement: pulmonary haemodynamics during exercise.Pulmonary arteriovenous malformations emerge from the shadows.Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging.ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre.Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension.Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary.Experimental validation of the hyperpolarized 129 Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung disease.
P50
Q26750994-28BF5692-9BC2-4B22-8801-42B8148E8AB5Q28066523-72FE36E7-9357-47C0-A386-6805C8A99B60Q30464688-68C64E7F-94AB-474F-8BDE-EBFD84E13888Q33717010-43B96326-DBA2-4C2C-BABA-15F24D5ACE02Q33805937-9474B800-6A53-4056-BFDD-951209CA7109Q34393150-C89FFE5F-9CD6-4246-9299-1F9FA1F9C74AQ35029607-2450C290-EAE4-4A5A-9FB4-30D92F9BFEA7Q35346528-E9C25C9F-9F6A-4DB1-81F2-0475E06E0E87Q35351007-C7C4FBD2-5317-4CBF-91B0-640C383FCA88Q35634008-8DAF4066-4C5A-4BA7-9F7D-D99B24631938Q36016540-8573AF79-79A5-4F20-A8DA-A65278BD2A03Q36811779-AE74F43C-DD11-4942-9A88-46951485EDF9Q37216131-8D7F9F03-7FBC-47AA-AE02-A90F1F9361BDQ37552634-37269310-5E9E-4167-8610-A1ACC4A47E9FQ37726298-2D30B84A-EE3A-4AD9-AA52-7E1E188AF28FQ37991302-E83B177B-C305-438A-ACAD-C2824A1ACAD5Q38721118-9E1116A0-A9E1-4D14-8AC4-93C3D694CD12Q38887196-6ED1A9A4-5E29-4AC7-BB8E-6AAB69C5C420Q39132518-4435339C-435C-4D13-98CB-64FBCACF2FDFQ39368666-40F0B78E-6EEC-47E1-8298-2EC170D15233Q39994626-ADE4C0FD-2191-4B44-A647-8ECEF6E33C85Q40061391-DF3BBD3B-71E4-4E85-A1BE-92EAF6AD3C11Q40185966-AC5C2569-4BD8-453A-8AB8-E3750CFC75A4Q40323205-289689AA-2299-4774-BCE7-57A7D028782CQ40957004-E8906F98-4E97-4616-9BFF-FAE5F1947E97Q42008785-6AF5DB1D-B389-453C-83E9-3380AF17EE38Q43559933-8063677C-8C56-4046-BB6F-FE2A75D2AC1DQ43908287-96167B59-D64C-479E-9EAC-CDE3056EFAD5Q44394935-DB3A281D-B5B9-4BE8-A102-33EA106E9BC8Q45760737-C184A8F4-D5E9-4C59-94A8-707A0315DBABQ46673537-7F5437D4-5903-4AFB-8715-4786F5A2FCA6Q47252990-80319DCC-1008-4838-B8BB-75A787E8BFB4Q47590789-294DC897-59B6-4016-BF06-0F4371351562Q47702289-CCD4133F-A586-41FB-BE03-A57171F069E0Q47710619-2EC21459-2AA8-4216-B661-C1C01661066DQ47835170-62AF5F68-2A43-477D-B893-B100F2C2B044Q48285191-F3580FE9-8088-4A12-97DE-0BE811909706Q48910821-B0F683A1-A5A2-4060-9BC0-37DBF7F7A223Q49390371-4FD40597-6059-4E59-A02E-7A16C26B9411Q50463055-C0663AC0-DE8E-4B0D-B506-D14A16F77393
P50
description
investigador
@es
researcher
@en
name
Robin Condliffe
@en
Robin Condliffe
@nl
type
label
Robin Condliffe
@en
Robin Condliffe
@nl
prefLabel
Robin Condliffe
@en
Robin Condliffe
@nl
P31
P496
0000-0002-3492-4143